Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Modeling the impact of PCSK9 inhibition on lipoproteins in dyslipidemia
2016-003551-30Phase 4Completed
- Sponsor
- Universitätsklinikum Freiburg
- Start
- Feb 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4 trial of alirocumab and evolocumab in dyslipidemia and lipid metabolism disorder (2 arms), sponsored by Universitätsklinikum Freiburg. Started Feb 2017; status: completed.
02
Drugs
alirocumabevolocumab
03
Conditions
dyslipidemialipid metabolism disorder
Beyond the preview
Go deeper on 2016-003551-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003551-30.